A Comparative study on the Risk Factor, Clinical Profile, and Outcome of Acute Myocardial Infarction in Patients of Age less than and more than 40 years by Geetha, M
A  COMPARATIVE STUDY ON THE RISK FACTOR, 
CLINICAL PROFILE, AND OUTCOME OF ACUTE 
MYOCARDIAL INFARCTION IN PATIENTS OF AGE 
LESS THAN AND MORE THAN 40 YEARS
Submitted to
THE TAMILNADU DR. M.G.R. MEDICAL UNIVERSITY
CHENNAI
In fulfilment of the regulations
for the award of the degree of
M.D. (GENERAL MEDICINE)
BRANCH - I
KILPAUK MEDICAL COLLEGE
CHENNAI.
MARCH 2010
BONAFIDE CERTIFICATE
Certified that the dissertation titled  “A  COMPARATIVE STUDY 
ON THE RISK FACTOR, CLINICAL PROFILE, AND OUTCOME 
OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS OF AGE 
LESS THAN AND MORE THAN 40 YEARS”  is a  bonafide work of the 
candidate  Dr.M.GEETHA, post graduate student,  Department of General 
Medicine, Kilpauk Medical College, Chennai – 10, done under my guidance 
and supervision, in partial fulfillment of regulations of The Tamilnadu Dr. 
MGR  Medical  University for  the  award  of  M.D.  Degree  Branch  I, 
(General Medicine) during the academic period from May 2007 to March 
2010.
Prof.G.Rajendran.M.D, 
Prof. & Head 
Department of General Medicine
Kilpauk Medical College, Chennai.
Prof. V.Kanagasabai,
The Dean 
Kilpauk Medical College
Chennai
 
ACKNOWLEDGEMENT
I thank Prof. Dr. V.KANAGASABAI , M.D., The Dean, Kilpauk 
Medical College for kindly permitting me  to use the resources and 
clinical material of this hospital.
I am grateful to  Prof. Dr. G. Rajendran, M.D.,  Professor and 
Head  of  the  Department  of  General  Medicine  for  his  constant 
encouragement and help during this study.
I  profusely  thank  Prof.  Dr.  N.  Senguttuvan,  M.  D.,  D.  M., 
Professor and Head of the Department of Cardiology for his guidance 
and encouragement.
I  am  grateful  to  Prof.  Dr.  N.Raghu  M.  D., Prof.  N. 
Dr.Gunasekaran M. D., for  their  guidance and support  during the 
course of the study.  I am indebted to Dr. S. Mayilvahanan M.D., Dr. 
I. Rohini M.D., Dr. P. Vasanthi M.D.,  for the support extended to me 
during the course of the study.
I thank  Mr. Siluvai,  statistician for his valuable time spent in 
analyzing the data and providing statistical support.
 I  also  thank  my  fellow  post  graduate  students  and  house 
surgeons for all the timely help they rendered.
Last but not the least, with sincere gratitude; I thank all the patients 
who cooperated to this study without whom this study would not have been 
possible.
CONTENTS
Sl.No. Title Page No.
1. INTRODUCTION 1
2. AIM 3
3. REVIEW OF LITERATURE 4
4. MATERIALS AND METHODS 27
5. RESULTS AND ANALYSIS 32
6. DISCUSSION 44
7. CONCLUSION 51
8. ANNEXURES
CHARTS
BIBLIOGRAPHY
PROFOMA
ABBREVIATION 
MASTER CHART
INTRODUCTION
INTRODUCTION
   
            Acute  myocardial  infarction  (AMI)  is  the  rapid  development  of 
myocardial necrosis caused by a critical imbalance between oxygen supply 
and demand of the myocardium. Myocardial infarction continues to be a 
significant problem in developed countries and is becoming an increasingly 
significant problem in developing countries. (1)
     Indians develop Coronary Artery Disease ( CAD) 5 to 10 years earlier 
than in other populations, and the occurence  of first myocardial infarction 
before the age of 40 years is 5 to 10 folds higher.(2) Even among Indians, the 
prevalence of CAD is not  homogeneous  and is  two fold higher in south 
indians. (3)
   Cigarette smoking has been the single factor very strongly associated 
with CAD in the young adult(4),  Perhaps of equal interest is the lack of a 
strong association of  other  traditional  risk  factors  to  CAD in the  young. 
Hypertension and lack of exercise are both firmly established risk factors for 
CAD  in  general,  but  they  appear  to  contribute  only  marginally in  this 
population.  (5) Numerous  studies  (6–9) have  demonstrated  the  surprisingly 
good prognosis up to three years after diagnosis of CAD in the young adult.
              In this study the risk factors, clinical presentation and short term 
outcome of myocardial  infarction in patients less than 40 years has been 
studied and compared with the older patients.
AIM OF THE 
STUDY
AIM OF THE STUDY
1. To  evaluate  the  modifiable  and  non-modifiable  risk  factors  of 
acute myocardial infarction in young (< 40 years).
2. To  study  the  clinical  profile  of  acute  myocardial  infarction  in 
young.
3. To study the short term outcome of acute myocardial infarction in 
young.
4. To  compare  the  young  (<  40  years)  with  older  patients  (>  40 
years) with reference to the risk factor, clinical profile, and short 
term outcome.
REVIEW OF 
LITERATURE
REVIEW OF LITERATURE
      The  conceptual  basis  for  considering  specific  “cardiovascular  risk 
factors” only emerged when the initial findings of the Framingham Heart 
Study began to appear in the early 1960s. A risk factor is a characteristic or 
feature  of  an individual  or  population that  is  present  early  in  life  and is 
associated with an increased risk of developing future disease.
       The risk factors are primarily considered under the following two 
categories
Conventional risk factors: (10)
Smoking  
Hypertension
Diabetes mellitus 
Hyperlipidemia  and  Elevated  Low-Density  Lipoprotein  Cholesterol 
High-Density Lipoprotein Cholesterol
Triglyceride-Rich Lipoproteins 
 Metabolic Syndrome, Insulin Resistance and Diabetes   
 Obesity
 Family history  
 Mental Stress, Depression, and Cardiovascular Risk
Novel atherosclerotic risk factors:
   High-Sensitivity C - Reactive Protein  
   Other Markers of Inflammation 
   Homocysteine  
   Fibrinogen and Fibrin D-Dimer 
   Markers of Fibrinolytic Function   
   Lipoprotein (a)
SMOKING:
     Cigarette smoking has been the single factor most strongly associated 
with CAD in the young adult. A strong dose response relationship between 
cigarette smoking and CAD has been observed in both sexes, in the young 
and in the elderly. More than 1 in every 10 cardiovascular deaths in the 
world in the year 2000 was attributable to smoking (11). 
                It  causes acute unfavorable effects on blood pressure and 
sympathetic tone, and a reduction in myocardial oxygen supply, enhanced 
oxidation  of  low-density  lipoprotein  (LDL)  cholesterol  and  impaired 
endothelium-dependent coronary artery vasodilation. (12)
           It  also increases  levels  of  CRP,  soluble  intercellular  adhesion 
molecule-1  (ICAM-1),  fibrinogen,  and  homocysteine(13),  spontaneous 
platelet aggregation, increased monocyte adhesion to endothelial cells, and 
adverse  alterations  in  endothelial  derived  fibrinolytic  and  antithrombotic 
factors,  including  tissue-type  plasminogen  activator  and  tissue  pathway 
factor inhibitor.
            Compared with nonsmokers, smokers have an increased prevalence 
of coronary spasm and reduced thresholds for ventricular arrhythmia. Even 
among non-smokers, passive exposure increases the incidence of coronary 
artey disease.  Studies suggest  that  compared to  non- smokers  those who 
consume 20 or more cigarettes per day have a twofold or threefold increased 
risk of coronary artery disease. (14)
            Smoking in the presence of other coronary risk factors appear to 
have synergistic effect on cardiovascular disease morbidity and mortality. (15) 
HYPERLIPIDEMIA:
     Abnormalities  in  plasma  lipoproteins  and  derangements  in  lipid 
metabolism rank among the most firmly established and best understood risk 
factors for atherosclerosis. Atherosclerotic involvement of coronary arteries 
is well established in men by young adult hood.(16) 
Current ATP III guidelines recommend lipid screening in all adults 
>20 years. ATP III guidelines strive to match the intensity of treatment to an 
individual's risk. A quantitative estimate of risk places individuals in one of 
three treatment strata.
The  first  step  in  applying  these  guidelines  involves  counting  an 
Individual’s risk factors.  Individuals with fewer than two risk factors fall 
into the lowest treatment intensity stratum  [LDL goal<160 mg/dL]. In those 
with two or more risk factors, the next step involves a simple calculation 
that estimates the 10-year risk of developing coronary heart disease (CHD) 
Those with a 10-year risk <20% fall into the intermediate stratum [LDL goal 
<130 mg/dL].  
Those with a 10-year CHD risk of >20%, any evidence of established 
atherosclerosis, or diabetes (now considered a CHD risk-equivalent) fall into 
the most  intensive treatment  group [LDL <100 mg/dL].  Members  of  the 
ATP III panel have recently suggested 70 mg/dL as a goal for very high risk 
and as an optional goal for high-risk patients based on recent clinical trial 
data. (17)
         Both hyperlipidemia and hypertriglyceridemia are important  risk 
factors  for  coronary  artery  disease.  A  10  percent  increase  in  the  serum 
cholesterol result in 20 –30 % increase in the risk of coronary artery disease. 
if it occurs early in life it may be associated with higher increase in risk. (11)
           The risk of CAD is positively correlated with serum total cholesterol 
concentration, which in turn is highly correlated with LDL levels. LDL has 
been found to be pro-inflammatory, elevated LDL appears to be involved 
with all stages of atherogenesis. 
             Endothelial dysfunction, plaque formation and growth, plaque 
instability  and disruption and thrombosis,  Elevated levels  of  LDL in the 
plasma leads to increased retention of  LDL particles  in the arterial  wall, 
their oxidation and secretion of various inflammatory mediators and chemo 
attractants.
       Although LDL is the primary lipid risk factor, other lipids increase 
the risk of CAD with or without LDL.
          The  combination  of  elevated  concentrations of  triglycerides,  small, 
dense  LDL  and  low  levels  of  HDL  is  referred  to  as  Atherogenic 
dyslipidemia. Meta analysis of multiple prospective studies, strongly suggest 
that elevated serum triglycerides are an independent risk factor for CAD. (18) 
          Two  important  mechanisms  by  which  HDL  is  thought  to  play  a 
protective role against atherosclerosis are reverse cholesterol transport and 
inhibition of LDL oxidation. (11) HDL could ferry cholesterol from the vessel 
wall, augmenting peripheral catabolism of cholesterol. HDL can also carry 
antioxidant enzymes that may reduce the levels of oxidized phospholipids in 
atheromatous lesions, which might enhance atherogenesis. Each increase of 
HDL cholesterol by 1 mg/dl is associated with a 2 to 3 percent decrease in 
risk of total cardiovascular disease.
        Isser  et  al.  (19) found  significant elevation  of  triglycerides and 
depression of high-density lipoprotein (HDL) cholesterol in young patients 
presenting with MI.
HYPERTENSION:
               Major overviews and randomized trials continue to demonstrate 
that blood pressure reductions as small as 4 to 5 mmHg result in large and 
clinically  significant  reductions in  risk coronary  heart  disease  in  middle-
aged subjects, the elderly, and high-risk groups, such as those with diabetes 
and peripheral arterial disease.(20,21) 
         Both systolic  and diastolic  hypertension have a  strong positive, 
continuous and graded relationship to CAD.
The  potential  mechanisms  by  which  hypertension  causes  coronary 
events  include  impaired  endothelial  function,  increased  permeability  to 
lipoproteins, increased adherence to leucocytes, increased oxidative stress, 
hemodynamic  stress  triggering  plaque  rupture  and  increased  myocardial 
wall stress and oxygen demand. (2)
The JNC VII report has also suggested a new classification of blood 
pressure, with normal defined as less than 120 mmHg systolic and less than 
80 mmHg diastolic.
 “Prehypertension”  defined  as  systolic  blood  pressure  120  to  139 
mmHg or diastolic blood pressure 80 to 89 mmHg. Stage 1 hypertension 
(systolic blood pressure 140 to 159 mmHg or diastolic blood pressure 90 to 
99 mmHg) or stage 2 hypertension (systolic blood pressure higher than 160 
mmHg or diastolic blood pressure higher than 100 mmHg).(17)
DIABETES:
   Diabetes is diagnosed if the fasting blood sugar is > 126 mgs/dl or 2 – 
hour plasma glucose more than 200mgs/dl. (22)
    Diabetes (both type I and II) increases the risk of CAD by 2- 4 times. 
Approximately  25% of  MI  survivors  have  diabetes.  Once  a  type  II  DM 
patient suffer an MI, their prognosis for recurrent MI and survival is much 
worse  than  that  of  CAD  without  DM.  Diabetes  absolutes  the  usual 
protection  from  CHD  afforded  for  a  premenopausal  women.  Diabetic 
women have twice the risk of recurrent MI compared to diabetic men. 
             Mechanisms by which DM causes atherosclerosis includes low 
HDL-C,  high  triglycerides,  increased  lipoprotein  remnant  particles, 
increased  small  dense  LDL-C,  elevated  lipoprotein  A  concentration, 
enhanced lipoprotein oxidation, glycation of LDL-C, increased fibrinogen, 
increased  platelet  aggregability,  increased  CRP,  PAI-I,  impaired 
fibrinolysis, increased VWF, hyperinsulinemia.(11)
        The abnormal lipoprotein profile associated with insulin resistance, 
known  as  diabetic  dyslipidemia,  accounts  for  part  of  the  elevated 
cardiovascular risk in patients with type 2 diabetes. While diabetic patients 
often have LDL cholesterol levels near average, the LDL particles tend to be 
smaller  and  denser,  and,  therefore,  more  atherogenic.  Other  features  of 
diabetic dyslipidemia include low HDL and elevated triglyceride levels. (17)
               The in- hospital mortality from MI in patients with diabetes is 1.5 
to 2 fold higher than non- diabetics. The worse clinical outcome of patients 
with DM is the acute phase of infarction include 
          1. The diffuse nature of coronary atherosclerosis 
          2. Reduced ability to develop collateral blood flow
          3. An abnormal pattern of exogenous substrate use in the setting of 
ischemia leading to increased oxygen consumption by myocardium. (23)
METABOLIC SYNDROME:
The ATP III guidelines now recognize this cluster of risk factors and 
provide criteria for diagnosis of the "metabolic syndrome"(24)
Abdominal obesity
   a. Men (waist circumference)  > 102 cm  (>40 in.) 
   b.Women   > 88 cm (>35 in.) 
Triglycerides >1.7 mmol/L  (>150 mg/dL) 
HDL cholesterol   
  a.Men  <1.0 mmol/L  (<40 mg/dL) 
  b.Women  <1.3 mmol/L  (<50 mg/dL) 
Blood pressure  130/85 mmHg 
Fasting glucose  >6.1 mmol/L  (>110 mg/dL).
           Accelerated  and  premature  CAD in  Indians  is  attributable  to  the 
metabolic syndrome (25)
          However, not all those with metabolic syndrome have similar risk. 
Most importantly, endothelial inflammation is now recognized as a major 
component  of  metabolic  syndrome  (26) and  the  most  recent  definition  of 
metabolic  syndrome  from the  National  Heart,  Lung,  and Blood  Institute 
includes a pro-inflammatory state. (27) Thus, inflammatory biomarkers such 
as hsCRP may help further stratify clinical risk and improve the prognostic 
value of metabolic syndrome.
OBESITY:      
              Obesity accelerates the progression of coronary atherosclerosis in 
adolescent and young adult men. (28)
        Obesity  is  associated  with insulin  resistance,  hypertension,  type 2 
DM, hyperinsulinemia, low HDL, hypertriglyceridemia, small dense, LDL, 
raised  CRP,  thrombosis  ,  diastolic  dysfunction  and  left  ventricular 
hypertrophy (11)
    Three key anthropometric measurements are important to evaluate 
the degree of Obesity — weight, height, and waist circumference. 
             Excess  abdominal  fat,  assessed  by  measurement  of  waist 
circumference or waist-to-hip ratio, is independently associated with higher 
risk for diabetes mellitus and cardiovascular disease
South Asians and Chinese  
  Men >90 cm (35 in)
  Women >80 cm (31.5 in)
The body mass index (BMI), calculated as weight (kg)/height (m)2      
BMI    kg/ m2 Obesity Class Risk of Disease
underweight <18.5
Healthy weight 18.5-24.9
Overweight 25.-29.9 Increased
Obesity 30.0-34.9          I High
Obesity 35.0–39.9           II Very high
Extreme obesity        >40           III Extremely high
FAMILY HISTORY:
      A family history of premature atherosclerosis, increases the risk of 
atherosclerosis in an individual likely as a result of environmental factors 
and a genetic predisposition to the disease.(29)
 A growing body of evidence, for example, shows that specific lipid 
abnormalities may be genetically transmitted to the offspring of patients with 
severe CAD. Uiterwaal et al. (30) found lower levels of HDL3 cholesterol and 
apolipoprotein A2  in  male  children  of  CAD  patients.  Similar  but  more 
modest trends were also identified in the female children of these patients.
SOCIOECONOMIC STATUS:
             Persons with low socioeconomic status are at high risk for CAD. 
Risk  factors  for  atherosclerosis  as  smoking,  hypertension,  obesity  and 
sedentary lifestyle are high in this economic group.
        Some  of  these  risk  factors  as  well  as  the  psychomotor  stressors 
increase the exposure to CAD. They also have less access to care. (11)
POST MENOPAUSAL STATE:
      After menopause, coronary risk accelerates in women. At least part 
of the apparent protection against CHD in premenopausal women derives 
from their relatively higher HDL levels compared with those of men.
             After menopause,  HDL values fall  in concert with increased 
coronary  risk.  Estrogen therapy lowers  LDL cholesterol  and raises  HDL 
cholesterol, changes that should decrease coronary risk.
             Young women with CAD comprise an especially interesting group 
given the protective effect of estrogen, but which factors are predictive in 
this  distinctly  unusual  cohort  is  poorly  understood.(31)  Anecdotal  cases 
suggest that diabetes in women may have a more powerful role than in men. 
Women who smoke have a quantitatively similar risk as men,  (32) but more 
than five times the risk of nonsmoking women.(33) 
Smoking  in  combination  with  oral  contraceptives poses  a  13-fold 
increase  in  CAD  mortality.(34) Truncal  obesity and  increased  body  mass 
index  (BMI)  have  recently  been  proposed as  potential  independent  risk 
factors, particularly in young women with CAD.
NOVEL ATHEROSCLEROTIC RISK FACTORS:
      Although the use of global prediction models like those developed in 
Framingham greatly improves the detection of heart disease risk, as many as 
20 percent of all events occur in the absence of any of the major  classic 
vascular  risk factors.  Thus,  because  of  the considerable  need to improve 
vascular  risk  detection,  much  research  over  the  past  10  or  15  years  has 
focused on the identification  and evaluation of  novel  atherosclerotic  risk 
factors. (35)
HIGH-SENSITIVITY C-REACTIVE PROTEIN
   The acute-phase reactant,  CRP, a simple downstream marker of 
inflammation,  has  now emerged  as  a  major  cardiovascular  risk  factor.(36) 
Composed of  five  23-kDa subunits,  CRP is a  circulating member  of  the 
pentraxin  family  that  plays  a  major  role  in  the  human  innate  immune 
response
         More than simply a marker of inflammation, CRP may influence 
directly  vascular  vulnerability  through  several  mechanisms,  including 
enhanced expression of local adhesion molecules, increased expression of 
endothelial PAI-1, reduced endothelial nitric oxide bioactivity, altered LDL 
uptake  by  macrophages,  and  colocalization  with  complement  within 
atherosclerotic  lesions.  Moreover,  expression  of  human  CRP  in  CRP-
transgenic mice was found to directly enhance intravascular thrombosis.(37)
hsCRP levels less than 1, 1 to 3, and higher than 3 mg/liter should be 
interpreted  as  lower,  moderate,  and  higher  relative  vascular  risk, 
respectively,  when  considered  along  with  traditional  markers  of 
risk..(38, 39,40, 41).
              hsCRP adds prognostic information at all levels of LDL cholesterol 
and at all levels of risk, as determined by the Framingham Risk Score. In 
other major studies, hsCRP levels predicted subsequent risk better than LDL 
cholesterol level.
OTHER MARKERS OF INFLAMMATION : (10)
              Although hsCRP is by far the best-characterized and most reliable 
inflammatory  biomarker  for  clinical  use,  several  other  markers  of 
inflammation have shown promise in terms of predicting vascular risk. 
These  include  cytokines  such  as  interleukin-6,  soluble  forms  of 
certain  cell  adhesion  molecules  such  as  intercellular  adhesion  molecule 
(sICAM-1), P-selectin, or the mediator CD40 ligand, as well as markers of 
leukocyte activation such as myeloperoxidase. Other inflammatory markers 
associated with lipid oxidation such as lipoprotein-associated phospholipase 
A2 and pregnancy-associated plasma protein A have also shown promise
HOMOCYSTEINE: (10)
          Homocysteine is a sulfhydryl-containing amino acid derived from the 
demethylation of dietary methionine. Patients with rare inherited defects of 
methionine metabolism can develop severe hyperhomocysteinemia (plasma 
levels  higher  than  100μmol/liter)  and  have  markedly  elevated  risk  of 
premature atherothrombosis as well as venous thromboembolism. 
 Mechanisms  suggested  to  account  for  these  effects  include 
endothelial  dysfunction,  accelerated  oxidation  of  LDL  cholesterol, 
impairment  of  flow-mediated  endothelium-derived  relaxing  factor  with 
subsequent  reduction  in  arterial  vasodilation,  platelet  activation,  and 
oxidative stress.
In  contrast  to  severe  hyperhomocysteinemia,  mild  to  moderate 
elevations of homocysteine (plasma levels higher than 15μmol/liter) are 
more common in the general population, primarily because of insufficient 
dietary intake of folic acid. Despite reduced enthusiasm and lack of evidence 
that homocysteine reduction lowers risk, there remain a few specific patient 
populations  for  whom  homocysteine  evaluation  may  prove  appropriate, 
including those lacking traditional risk factors,  with renal failure, or with 
markedly  premature  atherosclerosis  or  a  family  history  of  myocardial 
infarction and stroke at a young age.(42)
FIBRINOGEN AND FIBRIN D DIMER:
 Plasma  fibrinogen  influences  platelet  aggregation  and  blood 
viscosity,  interacts  with  plasminogen  binding  and,  in  combination  with 
thrombin,  mediates  the  final  step  in  clot  formation  and  the  response  to 
vascular injury
      Fibrin  D-dimer  reflects  the  extent  of  fibrin  turnover  in  the 
circulation, and epidemiological evidence has found D-dimer levels to have 
modest predictive value for future vascular events. 
            Following myocardial  infarction,  D-dimer  levels  also predict 
recurrent events and, like CRP, D-dimer predicts poor outcome in troponin-
negative ischemia.(43)
MARKERS OF FIBRINOLYTIC FUNCTION: (10)
            Impaired fibrinolysis can result from an imbalance between the clot-
dissolving enzymes t-PA or urokinase-type plasminogen activator and their 
endogenous inhibitors, primarily PAI-1. Plasma levels of PAI-1 peak in the 
morning,  whereas  concentrations  of  t-PA  demonstrate  a  less  prominent 
circadian variation. 
On this  basis,  a  relative  hypofibrinolytic  state  may  prevail  in  the 
morning that, along with increased platelet reactivity, may   contribute to the 
increased risk of myocardial infarction seen during this period. The clinical 
use of fibrinolytic markers to determine coronary risk offers only marginal 
value,  and no data available  suggest  that  measures  of  fibrinolysis  add to 
traditional risk scores.          
LIPOPROTEIN (a): (10)
Lipoprotein(a)  (Lp[a])  consists  of  an  LDL  particle  with  its 
apolipoprotein B-100 (apo B-100) component linked by a disulfide bridge to 
apolipoprotein(a)  (apo[a]), The  close  homology  between  Lp(a)  and 
plasminogen  has  raised  the  possibility  that  this  lipoprotein  may  inhibit 
endogenous  fibrinolysis  by  competing  with  plasminogen  binding  on  the 
endothelium.  More  recent  studies  have  suggested  that  Lp(a)  binds  and 
inactivates  tissue  factor  pathway  inhibitor  and  may  upregulate  the 
expression of plasminogen activator  inhibitor,  further  linking lipoproteins 
and thrombosis.
 Lp(a) also colocalizes within atherosclerotic lesions and may have 
local  actions through oxidized phospholipids pathways.(44) Thus,  several 
mechanisms may contribute to a role of Lp(a) in atherothrombosis.
Recent data (45) suggest that elevated homocysteine and elevated Lp(a) 
are independent risk factors for  the development  of CAD in young men; 
however,  these  two factors  appear  to  interact  in  a  synergistic  fashion  to 
confer risk in young women
  
 OTHER FACTORS; (10,11)
Physical exercise reduces myocardial oxygen demand and increases 
exercise capacity, both of which correlate with lower levels of coronary risk. 
The  cardioprotective  effects  of  exercise  include  reduced  adiposity  and 
diabetes  incidence,  lowered  blood  pressure,  and  improvement  of 
dyslipidemia,  as  well  as  vascular  inflammation.  Exercise  also  enhances 
endothelial dysfunction, insulin sensitivity, and endogenous fibrinolysis.
MENTAL STRESS: 
Entirely unexplored areas like anger and psychosocial stress can add a 
significant  morbidity  and  were  associated  with  MI  and  coronary  artery 
calcification in young adults. (46)
   Both depression and mental  stress  predispose to increased vascular 
risk. The adrenergic stimulation of mental stress can augment myocardial 
oxygen requirements and aggravate myocardial ischemia. Mental stress can 
cause  coronary  vasoconstriction,  particularly  in  atherosclerotic  coronary 
arteries, and hence can influence myocardial oxygen supply as well. Studies 
have further linked mental stress to platelet and endothelial dysfunction, the 
metabolic syndrome, and the induction of ventricular arrhythmias. (10)
  Congenital coronary artery anomalies can present for the first time as 
MI  in  young  adults.  Cases  of  myocardial  bridging,  where  the  coronary 
arteries are embedded within a tunnel in the myocardium beneath a layer of 
muscles,  have  also  been  reported  in  young  people  presenting  with  MI. 
Myocardial  bridging  can  result  in  significant  ischaemia  during  systolic 
contraction and can result in MI. (47 – 49)
CLINICAL PRESENTATION:
Chest  pain  is  the  commonest  presenting  symptom.  The  pain  is 
prolonged, usually lasting for  more than 30 minutes and frequently for a 
number  of  hours.  The  discomfort  is  described  as  constricting,  crushing, 
oppressing, or compressing; often the patient complains of a sensation of a 
heavy weight or a squeezing in the chest.
The classic  presentation  of  worsening angina culminating  in  MI is 
rare in younger patients. The first onset of angina that rapidly progresses to 
fully evolved MI is often the case in younger patients. (50)
     Atypical presentations of AMI include the following:
1. Heart  failure  (i.e.,  dyspnea  without  pain  beginning  de  novo  or 
worsening of established failure); 
2. Classic  angina  pectoris  without  a  particularly  severe  or  prolonged 
episode; 
3. Atypical location of the pain; 
4. Central nervous system manifestations, resembling those of stroke,
secondary to a  sharp reduction in cardiac output  in a  patient  with 
cerebral arteriosclerosis;
5. Apprehension and nervousness;
6. Sudden mania or psychosis;
7. Syncope; 
8. Overwhelming weakness;
9. Acute indigestion; and
10.  Peripheral embolization.
   Approximately  one  fourth  of  patients,  MI  is  associated  with  no 
symptoms at all. (51)
PHYSICAL EXAMINATION:
The physical examination can often be unremarkable. (10, 11, 17)
• Patients with ongoing symptoms usually lie quietly in bed and appear 
pale and diaphoretic. 
• Hypertension  may  precipitate  MI,  or  it  may  reflect  elevated 
catecholamine  levels  due  to  anxiety,  pain,  or  exogenous 
sympathomimetics. 
• Hypotension may  indicate  ventricular  dysfunction due to ischemia. 
Hypotension  in  the  setting  of  MI  usually  indicates  a  large  infarct 
secondary to either decreased global cardiac contractility or a right 
ventricular infarct. 
• Acute  valvular  dysfunction  may  be  present.  Valvular  dysfunction 
usually  results  from  infarction  that  involves  the  papillary  muscle. 
Mitral regurgitation due to papillary muscle ischemia or necrosis may 
be present. 
• Rales may represent congestive heart failure. 
• Neck  vein  distention  may  represent  pump  failure.  With  right 
ventricular failure, cannon jugular venous a waves may be noted. 
• Third heart sound (S3) may be present. 
• A  fourth  heart  sound  is  a  common  finding  in  patients  with  poor 
ventricular  compliance  that  is  due  to  preexisting  heart  disease  or 
hypertension. 
• Dysrhythmias may present as an irregular heartbeat or pulse. 
• Low-grade fever is not uncommon
SITE OF MI:
The site of myocardial infarction depending on the vessels occluded.
Left anterior descending (LAD) - Antroseptal MI
Left circumflex artery - Anterolateral MI
Right coronary artery - Inferoposterior wall MI
  With or without RVMI 
The site of MI based on the ECG findings.  (52)
1. Extensive Anterior wall MI : ST  segment elevation in leads I, AVL and 
anterior precordial leads .
2. Anteroseptal MI :  ST  segment elevation in  leads v1 to v4.
3. Anterolateral wall MI :  ST  segment elevation in leads I, AVL, V4 to V6.
4. Inferior wall MI : ST  segment elevation in leads II, III, AVF.
5. Inferolateral MI: ST segment elevation in leads II, III, AVF and V5 to V6.
6. Posterior wall MI: the following findings in leads V1 to V3.
• The mirror image of QS complex reflected by a all and widened 
R  wave                                                 
• The mirror image of ST segment elevation reflected by a widened ST 
segment depression.
• The mirror image of inverted T wave reflected by a tall, widened and 
upright T wave.
   7. Right ventricular MI: in the presence of inferior wall MI, ST segment 
elevation of 1mm or more in V1 ,V4R to V6R.
MATERIALS AND 
METHODS 
MATERIALS AND METHODS
POPULATION
Eighty  cases  of  acute  myocardial  infarction  were  chosen from the 
Intensive  Coronary  Care  Unit  at  the  Government  Royapettah  Hospital, 
Chennai from January 2009 – October 2009 for the study. Forty cases of age 
less than 40 years ( Group I )and forty  patients of age more than 40 years 
( Group II) were taken and the observations was made. 
INCLUSION CRITERIA
1. ECG  proven acute myocardial infarction.
2. Patients who underwent thrombolytic therapy.
EXCLUSION CRITERIA
1. Any contraindication to thrombolytic therapy.
2. Any myocardial infarction in past.
CONTRAINDICATION TO THROMBOLYTIC THERAPY (10)
Absolute Contraindication
• Any prior intracranial hemorrhage
• Known structural cerebral vascular lesion ( eg- arteriovenous 
malformation)
• Known  malignant  intracranial  neoplasms  (primary  or 
metastatic)
• Ischemic stroke within 3 months ( except acute ischemic stroke 
within 3 hr)
• Suspected Aortic dissection
• Active bleeding or bleeding diathesis ( excluding menses)
• Significant closed head or facial trauma within 3 months
Relative contraindications 
• History of chronic severe poorly controlled hypertension
• Severe  uncontrolled  hypertension  on  presentation   (  SBP  > 
180mmHg or DBP > 110mmHg)
• History of  prior  ischemic  stroke > 3 months,  dementia,  or  known 
intracranial pathology not covered in contraindications
• Traumatic or prolonged CPR ( > 10min) or major surgery with in 
3wks
• Recent ( within 2 – 4 wk)  internal bleeding
• Non-compressible vascular punctures
• For  streptokinase  :  prior  exposure  >  5  days  ago  or  prior  allergic 
reaction to the drug
• Pregnancy
• Active peptic ulcer
• Current  use  of  anticoagulants:  the  higher  the  INR  the  risk  of 
bleeding.
• A detailed history especially with reference to the presence of risk 
factors like diabetes mellitus, hypertension, smoking, obesity, family 
history,  hypercholesterolemia,  and  previous  history  of  coronary 
artery  disease  was  taken.  Age,  sex,  marital  status,  occupation, 
religion and time window were also noted. At the time of admission 
the pulse rate, blood pressure, Killip’s class, was noted and a detailed 
physical  examination  was done.  Laboratory  parameters  done were 
complete hemogram, blood sugar (fasting and post prandial), blood 
urea,  serum  creatinine,  serum  electrolytes,  serum  cholesterol, 
bleeding time and clotting time. ECG at the time of admission and 
after 6 hrs was taken and assessed for ST elevation and arrhythmias. 
Chest X rays were also taken. 
KILLIPS CLASS
Class I  :  no signs of pulmonary venous congestion
Class II : moderate  heart  failure,  as  evidenced  by  rales  over  less  than 
50% of lung, S3 gallop, tachypnoea, or signs of failure of the 
right side of the heart including hepatic and venous congestion  
Class III: severe heart failure,  pulmonary edema (with rales over more 
than 50% of the lungs).
Class IV: shock  with  systolic  blood  pressure  less  than  90  mmHg  and 
evidence  of  peripheral  constriction,  diaphoresis,  peripheral 
cyanosis, mental confusion and oliguria. 
All  patients  were  given  injection  pethidine  50mg  iv,  injection, 
promethazine  (25mg  iv),  aspirin  150  mg  OD,  clopidogrel  75  mg  OD, 
oxygen ( 2 – 4 l/ min) and IV heparin ( 5000 U 6th hourly for 5- 7 days).
All  patients  were  given  injection  Streptokinase  1.5  million  units 
dissolved  in  100ml  of  normal  saline  over  45  –  60  min.  Patients  who 
presented with high blood pressure, were treated with nitroglycerin infusion 
and then thrombolysed.
 Subsequently  during  the  following  days,  all  patients  in  both  the 
groups were started on Tab. Atenolol 50 mg once daily and  Tab. Enalapril 
2.5 mg once daily, provided there were no contraindications to therapy.
All these patients were intensively followed up for development of 
lung  signs,  bleeding  complications,  arrhythmias,  hypotension,  post 
infarction angina, reinfarcts and use of antiarrhythmic and other drugs. All 
patients underwent echocardiogram on day 6, prior to discharge.
Echocardiography  was  done  by HP Image  Point  machine  with 2D 
Echo,  M mode  and  Color  Doppler  study  was  done  in  all  patients  using 
parasternal and apical windows. The views studied were parasternal long 
axis,  parasternal  short  axis,  apical  4  chamberview and apical  2  chamber 
views. Features noted were 2D dimension of interventricular septum, left 
ventricular free wall, thickening of the walls, fractional shortening of Inter 
ventricular(IV)  septum and  free  wall,  studies  of  the  valves,  presence  of 
hypokinesia, akinesia or dyskinesia of IV septum and free wall. All patients 
were  screened  for  presence  of  effusion,  thrombus,  calcification  and 
vegetation.  Calculations  obtained were LV diastolic  volume,  LV systolic 
volume, fractional shortening and ejection fraction. 
Doppler  study  was  used  to  measure  LV inflow  pattern,  E/A  ratio 
(which denotes flow velocities across the mitral valve) to note the presence 
of diastolic dysfunction.
Both age groups were compared for sex, occupation, time window, 
site  of  infarct,  risk  factors  (diabetes  mellitus,  hypertension,  smoking, 
obesity,  family  history,  hypercholesterolemia,  and  previous  history  of 
coronary artery disease), the pulse rate, blood pressure, Killip’s class, ECG 
parameters, hemoglobin, blood sugar, serum cholesterol, LDL, HDL, TAG, 
arrhythmia, signs of failure, post infarct echo.
RESULTS AND 
ANALYSIS
RESULTS AND ANALYSIS
SEX
The patients were stratified into males and females in both group I 
(< 40 years) and group II (> 40 years)                                            
                                                  Table: 1
GROUP I GROUP II
MALE            38             28
FEMALE            02             12
There were two females in group I, whereas twelve females in group II. 
There is significant difference in the two groups (P value 0. 003).
OCCUPATION:                                           Table 2
Occupation        Group I             Group II
Professionals  and 
officials 3 3
Clerical 6 6
Manual laborers 25 16
House wife 1 10
Others 5 5
Occupation wise  MI was commonly seen in the manual labourers in both 
the groups, but the difference in two groups is not statistically significant. 
(P= 0.053)
SMOKING:   
                                                        Table: 3
Smoking  in  cigarette 
pack  years  Group I           Group II
0 7 21
<10 6 3
11 – 20 11 5
21 – 30 10 5
31 – 40 5 4
> 40 1 2
 (1 cigarette pack year = 20 cigarette/ day for 1 year)
33 patients in the group I and 19 patients in the group II were smokers.
7 patients were non smokers in group I and 21 patients were non smokers in 
group  II.  There  is  statistically  significant  difference  in  the  two  groups. 
(P = 0.030)
BMI:                                      
                                                        Table: 4
        GROUP I        GROUP II
NORMAL             01               00
OVER WEIGHT             10               05
OBESITY I             10               07
OBESITY II             17               24
OBESITY III             02               04
There is no statistically significant difference in BMI between the groups. 
(p = 0.281)
SITE OF INFARCT                           Table 5 
Site GroupI Group II
Inferior
IWMI 12 12
ILMI 6 2
IPL 2 5
Anterior AWMI 17 17
EAMI 3 4
Inferior wall MI was 12 in both the groups. Inferolateral MI was 6 in group I 
and 2 in group II. Inferoposterolateral MI was 2 in group I and 5 in group II.
Anterior wall MI was 17 in both the groups. Extensive Anterior wall MI was 
3 in group I and 4 in group II. The difference is not statistically significant. 
DIABETES MELLITUS:            
                                                               Table: 6
    Diabetes mellitus              Group I              Group II
Positive 5 20
Negative 25 20
In group I 5 patients were diabetic and in group II 20 were diabetic. The 
difference is statistically significant. (P < 0.001) 
HYPERTENSION:            Table: 7
      Hypertension              Group I              Group II
Positive 7 17
Negative 33 23
In  group  I,  7  patients  were  hypertensives  and  in  group  II,  17  were 
hypertensives. The difference is statistically significant. (P = 0.015)
FAMILY HISTORY:
                                                    Table: 8
Family  History  of 
IHD                Group I             Group II
Positive 25 11
Negative 15 29
 
Twenty five patients in group I and eleven patients in the group II had 
Positive family history of  IHD. This is statistically significant (P = 0.002).
TIME WINDOW:
Mean time window in Group I was 3.58 ± 1.80hrs. Mean time window in 
Group II was 3.22 ± 1.62 hrs. The difference is not statistically significant. 
(P =0.349).
PULSE RATE:
The mean pulse rate in Group I was 85.2 ± 14.87/min and 
Mean pulse rate in Group II was 90.05 ± 15.29 /min. There is no significant 
Difference in the two groups (P = 0.161).
SYSTOLIC BLOOD PRESSURE:       
                                             
                                                         Table 9
          
           Group I           Group II
  Normal               19               10
 Pre hypertension               12                 8
 Stage I                  5               16
 Stage II                 4                 6
Nineteen patients had normal systolic blood pressure in Group I and ten 
Patients had normal systolic blood pressure in Group II. The difference is
Statistically  significant. (P= 0.021)
DIASTOLIC BLOOD PRESSURE:         
                                                     
                                                 Table 10
      Group I       Group II
Normal              19                10
Pre hypertension              15                  8
Stage I               2                16
Stage II               4                  6
 Nineteen patients had normal diastolic blood pressure in Group I and 
ten  Patients had normal diastolic blood pressure in Group II. The difference 
isStatistically significant (P= 0.001).
Killip’s Class:                              
                                                    Table 11
GROUP I GROUP II
CLASS I
            
              35                 30
CLASS II
                
               3                  7
CLASS III                1                   2
CLASS IV
               
               1                   1
Thirty five patients in Group I and thirty patients in group II presented with 
killips class I. the difference is not statistically significant (P=0.509).
ST SEGMENT ELEVATION:
The mean ST elevation in Group I was 7.9 ± 2.95mm and in Group II was 
7.57±2.57mm  .The  difference  between  the  mean  is  not  statistically 
Significant. (P = 0.601)
FASTING BLOOD SUGAR:           
                                                     Table 12
         
           FBS        GROUP I        GROUP II
        < 125             34                22
        >125
           
              6
     
               18
            
 Six patients had high fasting sugar level in Group I and eighteen 
patients had raised fasting sugar levels in Group II. The difference is 
statistically Significant. (P=0.003)
POST PRANDIAL BLOOD SUGAR:       
                                             
                                                    Table 13
          PPBS        GROUP I         GROUP II
              <200                35                       22
              >200                   5                      18
Five patients had high post  prandial sugar level in Group I and eighteen 
patients had raised postprandial sugar levels in Group II. The difference is 
statistically significant. (P=0.001)
TOTAL CHOLESTEROL              
                                                    Table 14
           
           TC        GROUP I        GROUP II
        <200             30              25
        >200             10               15
Total cholesterol was high in ten patients in Group I whereas fifteen patients
 in Group II . The difference is not statistically significant. (P=0.228)
TRIACYL GLYCEROL:
                                                 Table 15
           TAG       GROUP I        GROUP II
             <150               27              22
             >150               13              18
Triglycerides was high in thirteen patients in Group I and eighteen patients 
in Group II .The difference is not statistically significant. (P=0.251)
LOW DENSITY LIPOPROTEIN: 
                                                 Table 16
        GROUP I          GROUP II
            <100               21                 15
             >100
         
              19                  25
         Low density lipoproteins was high in nineteen patients in Group I and 
twenty five patients in Group II .The difference is not statistically 
Significant. (P=0.178).
HIGH DENSITY LIPOPROTEIN:       
                                                         Table 17
        GROUP I          GROUP II
            Normal           11                16    
             Reduced
         
           
            29
              
           
             24
                 
           High density lipoproteins were low in twenty nine patients in Group I 
whereas in group II it was low in twenty four patients. The difference is not 
statistically significant. (P=0.178)
EJECTION FRACTION:      
                                                       Table 18
GROUP I GROUP II
LESS THAN 60%              12                29
MORE THAN 60%              38                    1
Ejection fraction was less than 60% in 12 patients in Group I and in 29 
Patients in Group II. The difference is statistically significant (P<0.001).
WALL MOTION ABNORMALITY
                                                   Table 19
           
      GROUP I       GROUP II
        PRESENT            23             26
          ABSENT            17            14
         
               Twenty three patients in Group I and 26 patients in Group II had 
wall  motion  abnormality.  The  difference  is  not  statistically  significant. 
(p=0.491)
REINFARCTION:               
  
                                                  Table 20
       GROUP I
 
      GROUP II
 
             ABSENT               39            36
            PRESENT                 1              4
   
Reinfarction  occurred  in  one  patient  in  Group  I  and  in  four  patients  in 
GroupII .The difference is not statistically significant. (P=0.166)
DEATH:
There was one death in group I and three in group II. The difference is not 
Statistically significant. (P=0.305)
DISCUSSION
DISCUSSION
            Premature CAD is a rapidly progressive form of atheromatous 
process (50) The risk factors  and short  term outcome of  acute  myocardial 
infarction in young adults varied from their elderly counterparts.
             Cigarette  smoking has been the single  factor  most  strongly 
associated with CAD in the young adult. Diabetes and hyperlipidemia are 
also frequently present in young CAD patients.
Whereas the importance of these factors in the pathogenesis of CAD 
and  their  powerful  relationship  to  rapid disease  progression  is  well 
documented (53,54) their importance in this population is not characterized in 
detail.
 
          In a study done by Kanitz MG et al to define the risk factors and 
clinical presentation of patients under age 40 who present to the emergency 
department  (ED)  of  a  community  hospital  with  an  acute  myocardial 
infarction  (AMI),  209  patients  were  studied.  The  major  risk  factor  was 
tobacco use 81%, followed by family history 40%, hypertension 26%, and 
hyperlipidemia 20%.(55) 
In the present study in patients under age 40, tobacco use was present 
in 82.5%, family history 62.5%, hypertension 52.5%,  hyperlipidemia 25%.
In  another  study conducted  by  Hong MK et  al,  631 patients  were 
studied. Their conclusions were, occurence of Acute myocardial infarction 
below  forty years was the predominant disease of men. Risk factor analysis 
revealed a history of cigarette smoking and hypercholesterolemia were more 
frequently found in the young patients, but a history of hypertension and 
diabetes were more frequently found in the elderly patients. (56)
 In this study in less than 40 years group, 95% were men, cigarette 
smoking  was  more  common  in  younger  patients,  whereas 
hypercholesterolemia was present in both groups. Hypertension and diabetes 
were more frequent in the elderly group.
  In  a  prospective  clinical  study  conducted  by  Fournier  et  al  108 
consecutive  Mediterranean  patients  with  AMI,  aged  <  40  years,  were 
prospectively  studied.  Clinical  features,  risk  factors,  and  in-hospital 
morbidity and mortality were evaluated. The most common risk factors were 
cigarette smoking 94.5% and hypercholesterolemia 48%.and that the short 
term prognosis was excellent.(57) 
The short  term outcome in  the  younger  patients  in  this  study  was 
better than the older ones.
                Stefanos Garoufalis et al conducted a study of risk factors 
comparing 460 patients and found that  family history and smoking were the 
most  common  risk  factors  in  patients  ≤45  years  old  P<0.04,  P<0.0001, 
respectively, and hypertension and diabetes mellitus were more prevalent in 
patients >45 years, P<0.00001 for both (58).
 In this study, we had similar results, with family history (P = 0.002), 
smoking (P = 0.030) being common in younger patients, and hypertension 
(P = 0.015) and diabetes (P <0.001).
Colkesen et al surveyed 25,038 patients and studied the risk factors 
and  found  that  Male  sex  was  more  prevalent  in  acute  MI  group  when 
compared with control participants (83 vs. 59%, respectively; P=0.01). 
A significant difference was found in cigarette smoking (62 vs. 36%, 
respectively; P=0.007) and family history (33 vs. 16%, respectively; P=0.03) 
between the two groups. (59) 
In another study, 9,373 patients were assessed for the frequency, risk 
factors,  presenting  symptoms,  treatment,  complications  and  in-hospital 
outcomes of  young patients and compared with those of  older patients.  . 
Risk factors such as tobacco use and a family history were more frequent in 
the young patients, whereas diabetes and hypertension were less frequent. 
Importantly, 66% of the patients aged <45 years had a history of tobacco 
use. Younger patients had a lower in-hospital mortality rate, lower incidence 
of  congestive  heart  failure  and  a  shorter  length  of  stay.  Multivariable 
analysis  of  in-hospital  mortality  revealed  that  older  age  remained  an 
independent predictor of death. (60)
SUMMARY
SUMMARY
• There were only 5% females in group I, whereas 30% in group II. The 
difference was statistically significant (P = 0.003)
• Acute myocardial  infarction was more common among the manual 
labourers  in  both  the  groups.  There  was  no  significant  difference 
between the groups.
• Smoking was more prevalent in group I compared to group II and the 
difference was statistically significant(P = 0.030)
• There was more number of diabetics in group II compared to that of 
group I. The difference was significant (p<0.001)
• Hypertension was less common in group I compared to group II and 
the difference was significant (P = 0,015)
• There was a significant difference in the distribution of family history 
between the groups suggesting a higher prevalence of family history 
of coronary artery disease in less than 40 years.(P = 0.002)
• Although there was no difference in body mass index (BMI) between 
the two groups, the body mass index was high in both the groups. 
(P=0.281)
• There was no difference between the groups in terms of site of infarct, 
pulse rate and time window.
• The  systolic  and  diastolic  blood  pressure  was  higher  in  group  II 
compared to that of group I (P=0.021 and <0.001 respectively)
• There was a no statistically significant difference in the ST segment 
elevation in the two groups (P = 0.601).
• There was no difference in the killip’s class between the two groups. 
• Group  II  had  raised  fasting  and  post  prandial  blood  sugar  levels 
compared to  group I,  with statistically  significant   P of  0.003 and 
0.001 respectively.
•  Total cholesterol, triglycerides, low density lipoproteins was elevated 
in both the groups,  but  the difference between the groups was not 
statistically significant.
• HDL was lower than normal in 29 patients in group I and 24 patients 
in group II, but the difference was not significant.
• There was better ejection fraction in Group I compared to Group II 
with a significant P value of < 0.001.
• There was no significant difference in reinfarction and death in the 
two  groups.
                                  
LIMITATIONS
LIMITATIONS
1. The sample size of forty may be a small number to draw conclusions, 
however  since  the  study  showed  significant  difference  in  the  risk 
factors and outcome, a study in a larger group is needed for further 
validation.
2. Estimation of novel atherosclerotic risk factors could not be done, due 
to unavailability of the tests .
3. Angiographic correlation could not be done, since the facility was not 
available .
4. The period of follow up in this study was short term, whereas a long 
term  follow  up  would  give  better  idea  about  the  outcome  of 
myocardial infarction.
CONCLUSION
CONCLUSIONS
• The frequency of risk factors in young patients differed from those in 
their  elderly  counterparts.  Smoking  and  family  history  were  more 
common risk factors in the younger age group, whereas diabetes and 
hypertension were common above 40 years. 
• There was no difference in the clinical presentation among the two 
groups.
• The ejection fraction was good in patients less  than forty years as 
compared to the older patients, signifying a better short term outcome 
in the young patients.
• Though reinfarction and death occurred more frequently in patients 
more than forty years, the difference was not significant.
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PROFOMA
PROFOMA
1. Name and address :                    2.  Age        yrs         3. Sex:
4.   Marital status :                          5. Occupation: 
6.   IP No:                                        7.  DOA:                   8. DOD: 
Diagnosis:
           SYMPTOMS
A.CHEST PAIN -                        (1) Yes             (2) No       (3) Non 
Specific
If yes, is it related to exertion?                             
  (1) Yes             (2) No       
CLASS -                                                                       1,2,3,4
DURATION OF ILLNESS      -                       1. Less than 6 hours
                                                                      2. 6 hours to 24 hours
                                                                      3. More than 24 Hours
     B.DYSPNOEA -                                  (1) Yes             (2) No       
If yes, is it related to exertion?                              
  (1) Yes             (2) No       
CLASS -                                                                       1,2,3,4
DURATION OF ILLNESS      -                        1. Less than 6 hours
                                                                           2. 6 hours to 24 hours 
                                                                            3. More than 24 Hours
  C.PALPITATION - Yes/NO                                 
  D.  SWEATING -   Yes/NO
  E. VOMITING –  Yes/No
  F. GIDDINESS –  Yes/No 
    G. EXTREME FATIGUE –  Yes/No
    H. SYNCOPE –  Yes/No
    I.  MISCELLANEOUS – 
RISK FACTORS AND PAST HISTORY
1. DIABETES MELLITUS -                     (1) Yes             (2) No       (3) 
Unknown
If yes no. of years           
          Whether on treatment  -  Yes/No         
2. HYPERTENSION      -                        (1) Yes             (2) No 
(3Unknown 
             If yes no. of years    -        
            Whether on treatment   - Yes/No          
          
3. SMOKING -                                          (1) Yes             (2) No       
If yes no. of years    -        
            How many cigarettes/day  - 
4. DYSLIPIDEMIA -                                (1) Yes             (2) No 
(3)Unknown
      5.FAMILY H/O  C.A.D  –                     (1) Yes                  (2)No 
(3)Unknown
6.ACID PEPTIC DISEASE                                         7. STROKE 
8.OTHERS
PREVIOUS TREATMENT
EXAMINATION
GENERAL
Consciousness                              anemia                               cyanosis 
clubbing 
Pedal edema                                 dyspnea                             cold extremities 
arcus senilis                                Xanthelasma                       others
VITAL SIGNS
Pulse                                       Blood pressure                        respiratory rate 
Temperature           
                        
CARDIOVASCULAR EXAMINATION
Jugular Venous Pulsation                                    Elevated or not 
Apical impulse                             
AUSCULTATION           S1                            S2
Apex
Tricuspid area
Pul. Area
Aortic area
 S3                              S4                                     1.Yes                     2.No
Murmur 
OTHER SYSTEM
RESPIRATORY SYSTEM
             Breath Sounds                                  Creps                      Rhonchi
ABDOMEN               
             Hepatomegaly                                                   Bruit 
COMPLICATIONS
      Circulatory failure                                              Killip’s class I, II, III,IV
      Arrhythmia                                                        
INVESTIGATIONS
             HB                                BT                              CT                     Bl Gp 
             FBS                             PPBS                       Total  Cholesterol
            TAG                              LDL                         HDL
CHEST X RAY:                
ELECTROCARDIOGRAM                                                       
    site of MI               Q                          ST             T                 Changes
   Arrhythmia                                 Chamber hypertrophy/Enlargement        
    
TREATMENT
REINFARCTION
FOLLOW UP   ECHOCARDIOGRAPHY
 EF                LVD              LVS                   Diastolic Dysfn 
Regional Wall Motion Abnormality 
Hypertrophy/Enlargement
Complications                                 MR              VSR               Effusion 
Clot
DEATH
                      
                                                                                                                 
MASTER CHART

MASTER CHART
GROUP I    ( MI IN < 40 Yrs)
S.No Age Sex OCC BMI DM SHT Cig FH SITE TW PR SBP DBP ST↑ Killip Class FBS PPBS TC TAG LDL HDL EF
Wall 
Motion
Reinf
arction DEATH
1 26 M 3 27 - - 9 + AW 5 88 180 94 12 I 72 126 120 88 84 45 70 + - -
2 32 M 5 23.4 - + 18 - AW 4 92 146 92 6 I 68 118 134 92 120 44 35 + - -
3 36 F 4 28.5 - + 0 - IW 6 87 158 110 4 I 97 112 254 187 132 38 67 + - -
4 32 M 2 29.3 - - 25 + AW 3.5 94 120 82 5 I 83 126 167 110 78 48 72 + - -
5 28 M 3 33.7 - - 12 + AW 2 110 110 72 6 I 64 109 145 91 98 45 75 - - -
6 39 M 3 30.4 - - 18 + ILW 0.5 64 128 84 7 I 98 132 123 76 104 46 65 - - -
7 31 M 1 29.0 - - 10 - AW 1 92 130 88 8 I 76 124 154 95 178 49 66 + - -
8 35 M 3 35.3 - - 21 + IW 7 71 96 54 11 I 99 138 198 102 96 51 72 + - -
9 40 M 3 32.1 - - 39 - IW&R 4 56 80 42 12 I 76 142 267 180 88 30 68 - - -
10 33 M 3 29.9 + - 28 - EAW 5 83 154 94 10 I 212 320 161 176 175 36 59 + - -
11 24 M 5 37.6 -   _ 6 + ILW 6 84 124 74 9 2 83 126 246 234 156 42 67 - - -
12 37 M 3 27.9 - + 22 + HL 1 78 160 96 8 I 91 143 186 123 150  44 40 + - +
13 39 M 3 38.4 - - 42 - AW 6 112 130 82 7 I 160 210 193 227 98  48 64 - - -
14 29 M 5 31.2 - - 14 - AW 2 120 128 78 6 I 88 156 146 78 104  49 66 + - -
15 36 M 3 34.2 - - 9 - AW 3 98 110 68 8 I 79 127 187 65 99 50 59 + - -
16 33 M 3 36.8 - - 18 + EAW 5 100 132 74 9 I 70 134 239 167 67 40 70 - - -
17 28 M 3 27.5 + - 0 + IW 6 71 100 62 4 I 148 240 129 198 78 48 38 - + -
18 37 M    3 39.4 - - 29 - AW 4 88 150 80 10 I 91 145 121 145 95 39 78 + - -
19 39 M 2 38.4 - + 0 + APL 1 74 148 94 14 2 83 115 236 102 108 41 65 - - -
20 23 M 3 30.6 - - 12 + AW 2.5 82 148 76 15 I 86 110 130 114 56 44 60      - -
-
S.No Age Sex OCC BMI DM SHT Cig FH SITE TW PR SBP DBP ST↑ Killip Class FBS PPBS TC TAG LDL HDL EF
Wall 
Motion
Reinf
arction DEATH
21 3o M 3 37.4 - - 32 + AW 1.5 88 130 76 5 I 65 112 134 98 84 41 60 + - -
22 35 M 3 31.3 - - 16 + IPL 4 92 110 66 6 I 78 136 136 76 145 48 67 - - -
23 34 M 2 29.7 - - 15 + AW 2 93 120 76 9 I 96 142 169 65 120 52 71 - - -
24 38 M 5 38.9 - - 28 - AW 6 84 114 76 4 I 86 116 175 124 68 42 72 - - -
25 40 F 2 36.4 - + 0 + IW 3 78 160 112 10 I 67 108 143 165 78 58 65 + - -
26 31 M 3 35.0 - - 24 + AW 4 88 130 86 11 I 95 122 180 102 138 44 59 + - -
27 37 M 3 30.1 + - 32 + AW 2 92 150 74 9 I 132 198 220 109 140 50 58 + - -
28 36 M 3 29.3 - - 12 - IW&RV 3 46 88 56 7 3 77 120 132 143 180 42 72 + - -
29 38 M 1 28.5 - + 18 + AW 4.5 112 170 98 5 I 98 142 140 128 55 40 64 - - -
30 27 M 2 37.5 + - 8 + EAW 6 92 108 58 9 4 156 302 287 286 76 30 49 - - -
31 30 M 2 34.9 + - 0 + HL 1 98 132 78 4 I 137 276 243 298 114 26 45 + - -
32 39 M 3 35.6 - - 24 - IL 1 76 128 74 8 I 79 154 125 82 130 41 69 + - -
33 37 M 3 33.7 - - 32 + AW 3 68 124 80 10 I 71 116 172 71 96 45 72 + - -
34 38 M 3 40.1 - + 38 + AW 5 92 130 90 11 I 69 107 134 96 88 48 59 + - -
35 35 M     1 38.2 - - 12 - AW 6 80 120 76 12 I 84 124 164 159 140 46 67 - - -
36 40 M     5 39.2 - - 22 - AW 3 68 110 60 6 I 83 139 257 212 77 51 70 + - -
37 26 M     3 38.9 - - 0 + IW 3 76 90 56 5 I 67 143 166 109 100 35 71 - - -
GROUP II (MI IN >40YRS)
S.No Age Sex OCC BMI DM SHT Cig FH SITE TW PR SBP DBP ST↑ Killip Class FBS PPBS TC TAG LDL HDL EF
Wall 
Motion
Reinf
arction DEATH
41 50 M 2 38.3 + - 42 + I&RW 2.5 94 88 46 8 3 320 412 348 161 I23 41 50 - - -
42 60 M     5 29.5 - - 28 - AW 4 104 120 76 10 2 73 126 132 195 99 43 52 + - -
43 60 F    4 42.3 - + 0 -   AW 3 114 140 88 5 I 79 142 154 102 112 33 42 + - -
44 45 M 3 38.6 + + 0 + IW 5 89 110 84 6 I 214 312 235 176 120 39 37 + - -
45 45 M 3 36.5 - - 12 - IW 2.5 98 100 80 9 2 88 165 124 123 116 52 49 - - -
46 50 F 4 35.2 + + 0 - IPL 6 102 140 80 4 I 164 21 276 236 140 30 40 + - -
47 75 M 3 38.3 - + 0 - AW 4 105 110 82 8 I 97 154 124 90 140 32 52 + - -
48 50 M 1 37.7 - - 24 + AW 5 114 130 86 6 I 91 102 132 79 100 46 55 + + +
49 65 M 5 34..5 + - 0 - EAW 0.5 88 150 102 9 I 187 210 187 156 108 44 42 + - -
50 48 M 3 33.5 + - 38 - IW&RV 6 70 88 50 4 I 198 298 235 167 148 34 58 - - -
51 70 F 4 29.3 + + 0 - AW 2 96 160 98 5 I 143 234 187 121 101 32 42 - - -
52 52 F 1 38.9 + + 0 + AW 7 64 170 102 6 I 186 254 124 95 98 39 49 - - -
53 54 M 3 38.5 + - 0 - AW 4 80 118 98 4 I 134 315 190 82 132 50 54 + - -
54 65 M 3 33.6 - - 28 - IW 3 80 110 70 9 I 82 128 241 183 95 42 55 + - -
55 50 M 3 36.8 - - 32 - AW 3 118 128 72 6 2 68 120 150 109 135 56 61 - - -
56 55 F 2 40.5 - + 0 - IPL 4.5 90 122 78 8 I 143 164 124 73 96 51 43 + - -
57 65 M 5 35.6 + - 12 + AW 2 76 140 88 10 I 125 226 138 77 140 46 33 + + -
58 57 F 4 29.7 - - 0 - EAW 1 94 130 80 4 2 87 135 127 80 119 29 55 + - -
59 59 M 3 28.9 - - 10 - IL 1 100 112 88 5 I 94 110 199 104 113 44 60 - - -
60 52 M     3 34.5 + + 8 - IW 2 110 110 72 8 I 176 345 250 189 168 38 43 + -
-
S.No Age Sex OCC BMI DM SHT Cig FH SITE TW PR SBP DBP ST↑ Killip Class FBS PPBS TC TAG LDL HDL EF
Wall 
Motion
Reinf
arction DEATH
61 60 F 4 37.3 + - 0 + AW 2 106 120 94 6 I 132 198 228 324 128 30 58 - - -
62 65 M 2 35.4 - + 37 -  AW 3.5 84 140 92 12 I 92 140 165 142 88 45 54 - - -
63 74 M 5 37.5 - - 0 + IW  4 60 120 68 8 2 84 126 176 121 92 43 55 + - -
64 60 M 2 38.4 + + 0 - IPL 4 80 150 98 12 I 154 265 248 188 112 57 39 + - -
65 58 F 4 39.5 - + 0 - AW 1 96 132 80 4 I 98 132 235 253 94 35 35 + + +
66 46 M 3 34.5 + - 41 - AW   1 84 148 94 7 2 134 243 256 245 125 38 48 + - -
67 70 M 5 35.7 - - 21 + AW 3 98 140 94 10 I 76 154 135 102 120 43 54 + - -
68 68 F    4 29.9 - - 0 - IL 2 82 90 52 9 I 64 132 142 98 86 44 48 - - -
69 60 M 1 43.5 + + 0 - AW 3 70 130 88 12 I 270 302 132 68 69 46 40 - - -
70 48 M 2 37.3 - - 24 - IPL 1 54 90 70 5 2 88 168 167 104 84 49 60 + - -
71 53 M 3 36.5 + - 12 + IW&RV 1 86 160 100 6 I 110 321 208 189 98 45 38 + - -
72 49 M 3 39.1 + - 8 - AW   5 110 130 92 9 I 137 213 298 298 180 50 45 + - -
73 60 F 4 37.8   - +   0 - EAW  4 106 120 90 11 4 105 143 139 108 112 37 58 _ - -
74 42 M 3 32.4 + + 0 - IW 3 74 122 98 13 I 125 247 143 187 120 44 54 - -
75 47 M 3 37.4 - + 32 - IW 3.5 90 80 48 4 I 99 176 320 239 124 49 32 + + +
76 60 M 2 35.7 + - 12 - AW 4 100 150 80 6 I 184 356 243 224 140 41 38 + - -
KEY TO MASTER CHART
• TW - Time Window
• DM - Diabetes Mellitus
• SHT - Systemic Hypertension
• Cig - Cigarette smoking in pack years
• FH - Family History of IHD
• Occu - Occupation
• PR - Pulse rate 
• SBP - Systolic BP 
• DBP - Diastolic BP 
• ST ↑ - ST segment elevation 
• EF - Ejection Fraction 
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• ST ↑ - ST segment elevation 
• EF - Ejection Fraction 
